biOasis Technologies Ord Shs V.BTI.H

Alternate Symbol(s): BIOAF

Healthcare Biotechnology

Bioasis Technologies Inc. is a Canada-based biopharmaceutical company focused on research and development of technologies and products intended for the treatment of patients with nervous system, including central nervous system, diseases and disorders. The Company is engaged in the development of its xB 3 platform, which is a peptide-based technology, for the transport of therapeutic agents, in particular biological products, across the blood-brain barrier (BBB). It is focused on both orphan drug indications, including brain cancers, and rare genetic neurodegenerative diseases and neuroinflammatory conditions. The Company is also focused on its Epidermal Growth Factor (EGF) platform for treating rare and orphan neurodegenerative and neuroinflammatory disorders. EGF is a protein that stimulates cell growth and differentiation, notably for myelin producing cells. Its development programs include xB3-001: Brain Metastases, xB3-002: Glioblastoma and xB3-007: Neurodegenerative Disease.

TSXV:BTI.H - Post by User

biOasis Technologies Ord Shs

Bullboard Posts

Comment by BearDownAZon Apr 03, 2017 1:55pm

109 Views

Post# 26069108

RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:Note to Recent Sellers...

Interesting artcle about the bee-venom peptide, apamin. Just a clarification about the protease-resistance. Apamin is a cyclic peptide, whereas Transcendpep is a linear peptide. The authors comment that the cyclic structure of apamin is resistant to protease degradation, whereas the linear peptides are not. This only refers to the BBB shuttle peptide, not the neurotherapeutic. It just means that the apamin portion of the molecule would be less susceptible to degradation than would be a linear BBB shuttle peptide like Transcendpep. The protease resistance of the rest of the "cargo" wouldn't be affected.

BDAZ

Bullboard Posts

Paramount Resources signs $3.32 billion asset sale